Robert Hoban Discusses the UN Vote on Narcotics

On Wednesday 4th November 2020 ACI hosted a members only conversation with Robert Hoban about the UN Vote on narcotics.  Robert Hoban is a leading cannabis attorney in the US as well as the cannabis commentator for Forbes magazine. You can read one of Robert’s articles here which was published by Forbes where he discussed the United States’ apprehension to legalise […]

ACI Statement on ACNFP’s CBD Clarifications

The ACI welcomes the recent clarifications from The Advisory Council for Novel Foods and Processes (ACNFP) relating to the data requirements for CBD novel foods applications. The ACNFP, who are an advisory committee to the FSA, highlighted the following key points, which emphasise the importance of ACI’s consortium approach to generating this data.

[Analytical Cannabis] The ACI Adds 16 CBD Companies to Its CBD Toxicity Trial

Sixteen CBD companies have signed up to a UK trial that will help determine the toxicity and safety of the popular cannabis compound.

The study, which has been organized by the UK’s Association for the Cannabinoid Industry (ACI), will involve 90-day-long tests on rodents to assess how CBD affects the liver, if it promotes drowsiness, and how it may interact with other drugs.

[Hemp Today] British CBD group says it may spend up to €1 million on tests

A British trade group says it has formed a consortium that may spend up to £1million (€1 million; $1.27 million) to carry out trials aimed at demonstrating the safety of CBD. The Association for the Cannabinoid Industry (ACI) said the research intends to answer questions posed by the UK’s Food Standards Agency (FSA).